Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer. Its lead product candidate is IMP321, a recombinant protein, which is in phase II clinical trials in metastatic breast cancer when used as a chemo-immunotherapy. The companys other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. It also develops CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The company has collaboration with NEC Corporation and Yamaguchi University. Prima BioMed Ltd. is based in Sydney, Australia.
